Patients with aggressive haematological malignancies such as leukaemias, lymphomas and myelomas are typically treated with chemo/ radiotherapy, broad-spectrum antibacterial
Tumour necrosis factor (TNF) is primarily secreted by monocytestmacrophages and activated T lymphocytes in response to fungal infections. TNF acts through TNF receptor 1 (TNFR1) triggering a pro-inflammatory response, and therefore plays a pivotal role in immune regulation and host immune responses. We hypothesized that single nucleotide polymorphisms (SNPs) in TNFRI gene may influence the innate immune response against Aspergillus. Three SNPs were genotyped in 275 individuals (144 immunocompromised haematological patients with high-risk of developing IPA and 131 healthy controls): TNFR1. 383(AlC) (rs2234649) and TNFR1~Gm (rs4149570) in the 5' UTR region, and TNFR1+ 36(AlG) SNP (rs767455) in the first exon of the gene. Ofthe 144 haematological patients, 77 patients developed Invasive Pulmonary Aspergillosis (IPA) infection and the remaining 67 patients were not infected. TNFR1+ 36(AlG) and TNFRI~Gmwere associated with IPA susceptibility (p=O.033 and p=O.OIS, respectively). A role ofTNFRl genetic variants in the susceptibility of patients to develop IPA was also supported by the significantly lower TNFRI mRNA expression level in IPA than in IPA-resistant patients and the strong correlation between the TNFRI-609 genetic variant and the expression levels of TNFRI. There was also a tendency for a higher frequency of galactomannan (GM) positivity in patients with TNFRI-609G/G genotype than in patients with TNFRl-609Gff (p=O.0909) or TNFRI -609Tff (p=O.0913) genotype. Predictive sequence analysis of the effects of TNFRI-609 promoter polymorphism revealed that this SNP might play a critical role in modifying the affinity oflCSBPIIRF-S, a transcription factor that is involved in the TNFRI-mediated activation ofNFldJ signalling pathway. Taken together, these data suggest that TNFRI polymorphisms influence the risk of IPA disease and might be useful for risk stratification strategies. These findings need to be confirmed in validation studies with larger samples of haematological patients. medications and/or corticoids. These therapies usually produce immunosuppression and severe neutropenia, which can be exploited by opportunistic pathogens such as Aspergillus fum igatus , which causes Invasive Pulmonary Aspergillosis (lPA), a deadly infection (I). This infection is acquired by inhaling the saprobic form of the fungal organism (conidia), commonly found in the human environment. The invasive stage of the disease is characterized by hyphal invasion and destruction of pulmonary tissue, which are most frequently observed in patients with pre-existing infections or lung damage (1-2). Despite the use ofnew antifungal drugs and the development of more sophisticated methods of diagnosis, the incidence of IPAcontinues to rise (3) .
Control of pulmonary infection with Aspergillus is critically dependent on the innate immune system and the release ofcytokines from T cells and myeloid lineage cells (4) , the first line of defence against Aspergillus. Phagocytosis of Aspergillus spores, is an early and critical event (5) , and its recognition by alveolar macrophages or dendritic cells (DCs) is rapidly followed by secretion of tumour necrosis factor (TNF) a. and other cytokines (6) .
TNFa. is a potent cytokine with a wide range of inflammatory and immunomodulatory activities and has been implicated in many inflammatory and infectious diseases (7) . The activities of TNFa. are dependent on the expression of two distinct receptors, TNFRI (TNFRSFIA, TNFRp55, CD120a) and TNFR2 (TNFRSFIB, TNFRp75, CD120b) which have different intracellular domains and mediate unique as well as overlapping functions, including activation of the transcriptional activator NFK~and programmed cell death (8) . Most signals, however, are transmitted by TNFRI, which can induce apoptosis and inflammation upon binding the transducing protein TRADD to its 'death domain' (9) . TNF receptors also play an important part in resistance to infection (10) , and there is some evidence that TNFa may have a critical role in IPA pathogenesis (11) (12) . There have been several reports that TNFa. can strongly promote the maturation and migration of immature dendritic cells (imDCs) from peripheral tissues to draining lymph nodes, where T-cell clonal expansion is stimulated (13) , and that it enhances the phagocytosis ofconidia by pulmonary alveolar macrophages or dendritic cells (DCs) (14) . Likewise, TNFa. augments the production of a wide variety of cytokines during infection (15) and potentiates the function of neutrophils, activating microbicidal mechanisms such as oxygen radical production (16) . In addition, an increased systemic production of TNFa. has been associated with resistance to systemic fungal infection (II, [17] [18] , while a predominant release of Th2 cytokines or TNFa. blockade has been correlated with the development of disease, delayed lung clearance ofAspergillus and increased mortality (5, 18) . Experimental studies with TNFRI knockout mice indicated that TNFRI is indispensable in host resistance against several infections and that treatment with anti-TNF monoclonal antibodies exacerbates disease and increases Th2 cytokines in mouse lung (19) .
Haematologic patients with similar clinical conditions and extrinsic risk factors vary in their susceptibility to IPA, suggesting a possible genetic predisposition to develop the disease. Identification of patients who are more susceptible to infection could facilitate the implementation' of effective prevention strategies. Genetic factors explain, at least in part, why some people resist infection more successfully than others, and gene disruptions can cause fatal vulnerability to specific pathogens (20) . Indeed, single-nucleotide polymorphisms (SNPs) in the promoter and coding regions of cytokine genes have been associated with changes in cytokine production or function (21) and may therefore influence susceptibility to infections. Thus, our group recently reported an association between a TNFR2 promoter polymorphism and a greater susceptibility to develop IPA (22) , and polymorphisms in ILl 0, IL6, ILl cluster and Toll-like receptors (TLRs) genes have also been described as risk factors for the infection (23) (24) (25) (26) . These data suggest that the Th response (involving cytokine and cytokine receptor genes) may modify the susceptibility to IPA.
The TNFRI gene, which has been mapped to 12p13 and consists of 10 exons is expressed in all nucleated cells. Several SNPs in the TNFRI gene have been previously described (27) . Hence, our working hypothesis was that TNFR I-related polymorphisms may play an important role in the development of IPA. This hypothesis was tested in a cohort study with 275 participants (144 haematological patients and 131 healthy controls) designed to identify whether some TNFR I genotypes or haplotypes could be considered as risk factor for development of IPA. Out of various polymorphic sites in TNFRI, the TNFRI_ 383 (AlC) (rs2234649) and TNFR1_ 60 9(Gff) (rs4149570) SNPs in the 5' UTR region and the TNFRI+ 3 6(AlG) SNP (rs767455) in the first exon were selected for genotyping because they have been reported as "functional SNPs" or associated with inflammatory and infection diseases (28) (29) (30) .
MATERIALS AND METHODS

Study populations and clinical diagnosis ofIPA
The present study was conducted at Virgen de las Nieves University Hospital, Granada (Spain). All participants enrolled were Caucasian and resident in the Granada urban area. All subjects (patients and healthy controls) gave their written informed consent to participate in the study, which was approved by the ethical review committee of our institution. The population consisted of 275 participants (144 immunocompromised haematological patients and 131 healthy controls). Haematological patients were treated at our department of Haematology from January 2004 to June 2008. The risk factors for IPA that were studied included: neutropenia, haematopoietic stem cell transplantation (HSCT), chemo/radiotherapy, and broad-spectrum antibiotic and high-dose corticoid therapy. Therefore, adult patients with haematological malignancies receiving treatment for chemotherapy were eligible for the study if their neutrophil count was expected to fall in the course of remission, induction or consolidation chemotherapy or peripheral stem cell transplantation. All patients who were included in this study had high-risk of developing IPA infection. This cohort was also chosen on the basis of availability of blood samples for testing. Part of this cohort was previously investigated to assess predictors of IPA susceptibility (22) (23) (24) (25) . Control subjects were blood donors recruited at the Regional Blood Transfusion and Tissue Center (Granada, Spain).
IPA was diagnosed in accordance with consensus criteria recently reported by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group (EORTC/IFICG) and the National Institute of Allergy and Infectious Diseases/ Mycoses Study Group (NIAID/MSG) (31) . The diagnosis was assigned by physician investigators in a blinded fashion. Clinical data were obtained by a detailed review of hospital records. Data were gathered on: site of infection; clinical signs (lower respiratory tract infection); presence of severe neutropenia for >10 days; persistent fever for >96 h refractory to appropriate broad-spectrum antibacterial treatment; signs and symptoms of graft versus host disease (GVHD), corticosteroid therapy in previous 60 days, fungal infection during previous neutropenia episode and galactomannan (GM) detection in > 2 blood samples. Laboratory data were also recorded.
Quantification ofserum galactomannan antigen
GM, a heat-stable heteropolysaccharide, is a cell wall component of Aspergillus. ELISA is a sensitive method to detect GM and is now included in IPA diagnostic protocols (31) . We used a commercial ELISA kit (Platelia ® Aspergillus; Bio-Rad. Marnes La Coquette, France) to detect GM antigen in serum, following the manufacturer's instructions and calculating the GM concentration from the dilution, giving the same optical density as the kit calibrator. The ELISA was performed twice weekly during hospital stay and then at each outpatient visit until the end of immunosuppressant or chemotherapeutic treatment. Concomitant treatments (piperacillintazobactam or amoxicillin-clavulonic acid) in each patient were reviewed to avoid false-positive GM results.
Single nucleotide polymorphism selection, genomic DNA isolation and genotyping
FASTSNP, a web server to identify putative functional SNPs of genes was used as first selection criterion for SNPs in TNFR1gene. A second selection criterion was the reported association ofTNFRl SNPs with inflammatory and infectious diseases (28) (29) (30) .
Genotyping of the promoter and coding regions of TNFRI gene for the selected SNPs (as listed on the NCBI internet database, http://www.ncbi.nlm.nih.govl) was performed on genomic DNA, which was isolated from 3 ml of EDTA-blood with a commercial kit (Real SSS DNA extraction kit, REAL, Madrid, Spain) and stored at -20°C until used in the experiments. The genomic DNA was used as a template in the polymerase chain reaction (PCR). TNFRI SNPs were detected in samples from haematological patients and controls by PCR-restriction fragment length polymorphism (PCR-RFLP), using primers that amplified a short fragment containing the SNP (Table I) (28, 30) . PCR was performed in a volume of 50 ul, containing -100 ng of template DNA, 0.2 IlM primers (Genotek, Bonsai Technologies Group, Madrid, Spain), 5X Green Buffer (Promega, Madison, WI, USA), 1.5 mM MgCl2 (Promega, Madison, WI, USA), 2 mM dNTPs (GeneCraft, Munster, Germany), 1 U of GoTaq Flexi DNA polymerase (Promega, Madison, WI, USA) and H 2 0 . For the determination of TNFRI +36(A1G) genotypes, the PCR conditions were: denaturation at 95°C for 10 min, 30 cycles of denaturation at 95°C for 30 sec, annealing at 67.5°C for 30 sec and elongation at 72°C for 20 sec, followed by a 5-min final extension at 72°C. For the determination ofTNFRI-XG([) genotypes, PCR conditions were: denaturation at 95°C for 120 sec and then 30 cycles of denaturation at 95°C for 30 sec; annealing at 55.2°C for 30 sec and extension at 72°C for 40 sec. This was followed by a final extension at 72°C for 5 min. Finally, TNFRI. 383(NC) genotypes were determined following a touchdown PCR protocol: denaturation at 95°C for 120 sec and then 15 cycles of denaturation at 95°C for 30 sec; annealing at 66.soC (decrease o.soc per cycle) for 30 sec and extension at 72°C for 20 sec. Then, 20 cycles of denaturation at 95°C for 30 sec, annealing at 59.5°C for 30 sec and extension at 72°C for 20 sec were performed. This was followed by a final extension at 72°C for 5 min. The two alleles at each polymorphic site were identified by incubating the PCR product with a restriction enzyme selected to cut one ofthe two alleles (Table I) , followed by electrophoresis on 3-5 % agarose gel ( Fig. 1) (28, 30) .
Hardy-Weinberg equilibrium test and statistical analysis ofTNFRI SNPs
Hardy-Weinberg Equilibrium (HWE) tests were performed by a standard observed-expected chi-square (X 2 ) test at each polymorphic site (http://ihg2.helmholtzmuenchen.de/cgi-bin/hw/hwal.pl). P<0.05 was considered significant. All variants had two alleles, and allele frequencies were determined by direct gene counting. Results were analysed by constructing 2x3 and 2x2 contingency tables to determine differences in genotypic and allelic frequencies of the studied polymorphisms among IPA patients, non-IPA patients and control subjects. P-values for association studies were calculated by means of the Pearson's X 2 test and Fisher's corrections. P< 0.05 was considered significant. The Stat Calc program (Epilnfo software; Center for Disease Control, Atlanta, GA, USA) was used for the data analysis.
Linkage disequilibrium and haplotype analysis
The expectation/maximization (EM) algorithm was applied to the genotype data obtained in order to estimate linkagedisequilibrium(LD) and haplotypefrequencies,using SNPStats software (Institut Catala d'Oncologia, Hospital Duran I Reinals, Barcelona, Spain), which is easy to use and freely available online at http://bioinfo.iconcologia.net/ snpstats/start.htm. Haplotype frequencies were compared between IPAand non-IPApatients.
RNA isolation and quantification of TNFRJ mRNA expression by comparative qPCR
Blood samples were collected in PAXgene blood RNA tubes (PreAnalytix, Qiagen) and they were inverted at least 10 times and stored at -80°C. After collection and storage, samples were thawed at room temperature 2:2 h and inverted at least three times before further processing. Total RNA was extracted according to the manufacturer's instructions using the PAXgene blood RNA isolation Kit (Qiagen, Valencia, CA). The quality and integrity of extracted RNA was measured using the Standard Chip of the Bio Rad Experion Automated Electrophoresis System (Bio-Rad Laboratories). The quantity of extracted RNA was determined by spectrophotometry (NanoDrop ND-lOOO UV-Vis Spectrophotometer, Nanodrop Technologies). Total RNA samples were then stored at -80°C until further processing.
For comparative qPCR analysis, one microgram of total RNA was reverse transcribed and amplified using Brilliant® II SYBR® Green QRT-PCR, AffinityScript" Master Mix, 2-Step (Stratagene) and specific primers (Eurogentec).
TNFR 1 primer sequences were designed in accordance with published gene sequences (Table I) Four micrograms (-2fJl) of reverse transcription mixture were amplified by comparative qPCR. The amounts of comparative qPCR products were determined . by using MXPro™ QPCR software v.4.00 (available at http://www.stratagene.com) and the Mx3005P system (Stratagene, USA). Gene expression values were calculated following the most common method for relative quantitation, 2-M CT method. The 2-M CT method enables relative quantitation through measurements of crossing thresholds (C T ) . The comparative differences between the TNFRI levels and an endogenous control (GAPDH) for each sample enable a relative quantitative comparison between the samples of IPA and non-IPA patients. Within the linear range of amplification, at least two values of each amplification product were calculated (Ct) and were normalized to the corresponding GAPDH values. When results were normalized, IPA and non-IPA values were compared, considering the mean of non-IPA patient values as reference (X axis). The gene expression values are given as Log2'~~~Ct (Fold change).
PCR conditions were: denaturation at 94°C for 10 min, then 40 cycles of 94°C for 30 sec and annealing at 60°C for 30 sec. A 103 bp fragment of GAPDH was coamplified in duplicate for each assay and PCR conditions were the same as for TNFR 1 amplification.
Statistical analysis ofclinical data
Relationships among clinical, radiological (chest radiography and computed tomography imaging) and microbiological data of IPA and non-IPA patients were evaluated as adjusted odds ratios (ORs) and 95% CIs derived from logistic regression analysis using Tabulated Data Epidemiological Analysis (EPIDAT) 3.1 version for Windows (available online at http://dxsp.sergas.es/ ApliEdatos/Epidat/cas/default.asp).
Transcription factor binding sites
Transcriptional regulation is a critical step in the expression of genotype as phenotype, Initiation of transcription is the key control point in gene transcription and is regulated by the direct interaction of transcriptionfactor proteins with DNA promoter regions called transcription factor binding sites (TFBSs). These interactions between DNA and proteins control the expression of the genes by activating or inhibiting the transcription machinery.
TFBSs are available in various databases, and the Transfac database has been widely used in studies on regulatory elements (REF) (32) . We investigated relationships ofinterest between TNFR 1.609(GfT) SNP and TF binding affinity by measuring similarities between human TRANSFAC TFBSs and the sequence containing TNFR1_ 609(GIT)' using the TOMTOM algorithm (33) . Because TFs bind to short parts ofthe TNFRI promoter region, it was necessary to define a fragment of the promoter sequence containing the TNFR 1_609(GIT) SNP considered a putative TFBS. For this purpose, we determined the length of the sub-sequence and the relative offset to the position of the TNFR1. 609(GIT) SNP. We selected a fixed length of 9 in accordance with the properties of TFBSs in the Transfac database. In order to cover all possibilities, sequences were generated using a window size of 9 nucleotides. Movement of the window across the sequence in 5'-3' direction yielded 9 sub-sequences for the TNFR1. 609 (GIT ) SNP that we considered putative TFBSs. Then, for each sub-sequence we measured the distance between each human TFBS by applying the TOMTOM algorithm (33) . We selected the most similar TFBSs and then compared the TFBSs obtained when the sequence has a "0" at position -609 with those obtained when the sequence has a "T" in that position.
RESULTS
Characteristics ofthe patient population
The authors conducted a based-population cohort study with 275 participants (144 immunocompromised haematological patients and 131 healthy controls). The healthy controls served to compare the frequency of mutations between the patient group and the general population. The main characteristics of study participants are summarized in Table II . There were no significant differences in gender distribution or mean age between haematological patients and controls.
The haematological group included 18 (12.50%) patients with acute lymphoid leukaemia, 50 (34.72%) with acute myeloid leukaemia, 17 (11.81%) with Hodgkin's disease, 26 (18.05 %) with non- Data are expressed as n (%). Haplotype frequencies and p values were estimated using the implementation of the EM algorithm coded into the SNPStats. p<O.05 was considered significant. (Table II) . There was a tendency for hemoptysis to be more frequent in IPA versus non-IPApatients (Table II) .
TNF-R: tumor necrosis factor receptor; AA: Amino acid; A/G: Adenine/Guanidine; G/T: Guanidine/Thymine
TNFRI: tumor necrosis factor receptor-I; OR: odds ratio; CI: confidence interval; G/G: Guanidine/Guanidine; A/T: Adenine/Thymine; A/G: Adenine/Guanidine; G/T Guanidine/Thymine
Association ofTNFRl variants with IPA infection
Three SNPs were genotyped in the TNFR I gene (rs2234649, rs4149570 and, rs767455). The distribution of TNFRI polymorphisms (genotypes and allele frequencies) was similar between haematological patients and healthy controls. These results are summarized in Table III . The genotype and allele frequencies of TNFR I polymorphisms in our control population were consistent with HWE criteria (p>0.05).
Because of the very low frequency «2.5%) of TNFR 1. 383 (N C) in the haematological patients and controls, this SNP was excluded from the association analysis. IPA and non-IPA patients significantly differed in the distribution of TNFR I. ;  Table IV ). Haplotype analysis was performed to further evaluate the role of TNFR 1 polymorphisms in IPA susceptibility. As expected, TNFR 1. 609 (Grr) and TNFRI+ 36 (A /G ) polymorphisms were in complete linkage disequilibrium (0'=0.7109). Haplotype analysis, in contrast with the results of single SNP analysis, showed no association of any haplotype with IPA infection (Global haplotype association p-value=0.280, Table V) .
Galactomannan analysis
A total of 1986 determinations were performed in duplicate in our patient cohort, and 334 (16.82%) were positive (index>0.5). A mean of 23.29 determinations were performed in duplicate for each IPA patient and a mean of 2.88 determinations in duplicate for each non-IPA patient. A trend toward a higher positive GM percentage was observed in patients with TNFR 1.609(Grr) genotype GG versus those with TNFR 1. 609 (Grr) genotypes GT or TT (p=0 .0909 and p=0.0913, respectively) ( Fig.  2) . No differences were observed when positive GM determinations were classified in relation to TNFR1+36(A/G) or TNFR 1. 383 (A/C ) genotypes. These results suggest that the TNFR 1.609(Gff) promoter variant rather than TNFRI+ 36(NG) might have a relevant role in IPA. TNFRI.609GG/GT patients are prone to develop IPA while TNFRI. 609TI patients appear to be resistant to infection. This influence of TNFRI. 609(Gff) may be explained by its ability to affect TNFRI mRNA and protein expression levels, producing a defective cell-mediated Th I immune response against fungal pathogens.
Cytokines are regulated both transcriptionally and posttranscriptionally, therefore, SNPs in transcriptional regulatory regions of cytokine genes can influence the amount of cytokine produced in response to inflammatory stimuli (35) . Thus, several polymorphisms in the TNFa gene have been broadly described and associated with susceptibility
DISCUSSION
TNFRI. 609 (GIT) polymorphism is located in a transcription binding site for leSEP
The potential functional effect of TNFR 1.609(Grr) SNP was investigated by scanning for TFBSs using the TOMTOM algorithm. The TNFRI. 609 G allele that determined susceptibility was found to encode a potential binding site for interferon consensus binding protein (ICSBP/IRF-8) (Fig. 4) . ICSBP/IRF-8 is an IFNy-inducible transcription factor ofthe IRF family that regulates transcription via multiple target DNA elements, such as IFN-stimulated response element (ISRE), Ets/IRF composite element and IFN-y activation site (GAS) (34) . In the absence ofT allele, the binding of ICSBP/IRF-8 to this region is predicted to be disrupted, potentially disturbing the transcriptional activation ( Fig. 4 ). We hypothesize that this putative TFBS might be involved in the initiation ofTNFR I transcription process. Therefore, the TNFR 1.609(Grr) polymorphism might be critical in the development of the innate immune response against fungal pathogens. respectively; Fig. 3B ). Taken together, these results strongly support our hypothesis suggesting that TNFRI_ 609 (Grr) polymorphism may be involved in IPA susceptibility. However, these results should be interpreted with caution because they are based on a limited number of samples.
In the present study we demonstrate that the TNFR 1.609(Gff) promoter variant is associated with susceptibility to IPA infection. This result might indicate that a decrease in the mRNA and probably in the protein levels of TNFRI may participate in molecular mechanisms that determine IPA susceptibility. However, further functional analysis is required to demonstrate a definitive correlation between TNFR 1.609(Gff) promoter polymorphism and TNFRI mRNA and protein levels. 
Downregulation ofTNFRI upon lPA infection
To further confirm the importance of the TNFRI signalling pathway and the TNFRI. 609(Grr) polymorphism in IPA susceptibility, comparative qPCR analysis was performed to measure differences in TNFRI mRNA expression between IPA (n=28) and non-IPA patients (n=9). Comparative qPCR revealed a significantly lower expression of TNFR I mRNA in IPA versus non-IPA patients (Fig. 3A) , which might also be related to the presence ofgenetic variants in the TNFR I gene promoter. Interestingly, the analysis ofTNFRI mRNA levels according to the TNFR 1.609(Grr) variant showed a significantly lower TNFRI mRNA level in G carriers (GIG or G/T) than in TIT genotype patients (p=O.0076 and p=O.0341, to pulmonary infection (36) . Although TNF was found to be involved in IPA susceptibility in animal studies (4), investigation by our group showed no association between IPA development and TNF polymorphisms (TNFu_ 308 (A/U ) and TNFu+ 489 (A/G )) or plasma TNF levels but a strong relationship with a TNFR2 promoter polymorphism (22) . Therefore, we hypothesize that variants in TNFR genes rather than TNF genes may contribute to the pathogenesis of IPA infection. The presence ofTNFR variants might explain the critical role of the TNFu pathway in this invasive fungal infection. The gene encoding TNFR I contains numerous polymorphisms (27) . This study assesses the effect on IPA susceptibility of two single nucleotide promoter polymorphisms at position -383 and -609 -009
[A) (8) I in the 5' upstream region and a polymorphism at position +36 in the first exon of TNFRI gene. To our knowledge, this is the first report of a candidate gene-association approach to describe a role for TNFRI gene in the pathogenesis ofIPA. The results obtained showed a significantly decreased risk of IPA in TNFRI+ 36GG and TNFRI_ 609TT homozygous patients. Unlike the results of single SNP analysis, haplotype analysis showed no association of any haplotypes with IPA infection. However, haplotype analysis might not be a valuable approach in this study, because of the low representation of the GT haplotype in both IPA and non-IPA populations.
There are also doubts about the functionality of the TNFRI + 3 6(AlG) polymorphism because there is a synonymous SNP that encodes Proline at codon 12 (CCAlCCG) , therefore haplotypes containing this SNP in the first exon of TNFR I may not have any biological significance. However, we cannot rule out the possibility that this TNFRI polymorphism may be in linkage disequilibrium with unidentified susceptibility polymorphisms that are responsible for the significant association observed. Taken together with results reported for TNFR2 polymorphisms (22) , these findings suggest that TNF receptor I and 2 genes play a role in IPA infection. An aberrant expression or funct ion of TNF receptors is likely involved in the development of IPA in haematological patients. Another finding in support of this hypothesis was the significantly more frequent % GM positivity in patients with GG genotype of TNFR1-609 (Grr) SNP than in those with GT or TT genotypes. These data strongly suggest that the TNFRI gene may determine susceptibility to IPA infection and that TNFRl _ 609 (Grr) polymorphism exerts a protective effect against IPA (expression of positive GM).
A possible explanation for the effects observed may be that the presence of TNFR 1_ 609 (Gff) promoter polymorphism influences TNFRI mRNA expression levels and may therefore be responsible for a defective Th I response against Aspergillus. Further, TNFRI _ 609(Grr) promoter polymorphism may affect serum GM levels via the regulation of the cell-mediated Th 1 response. This hypothesis was explored by measuring TNFRI gene mRNA levels in IPA and non-IPA patients. Interestingly, TNFRI mRNA expression was consistently lower in IPA patients than in non-IPA patients, suggesting that TNFRI plays a key role in IPA infection.
Additionally, we observed a positive correlation of TNFR I mRNA levels according to the TNFR 1.609(Gff) variant. Patients with TIT genotype showed higher levels ofTNFRI mRNA when compared with GIG or G/T genotype patients, suggesting that TNFR I. 609(T) polymorphism could be a functional SNP that regulates TNFR I mRNA expression. Thus, T carriers could have a higher TNFRI protein expression that could confer a major resistance to infection through a more efficient cell-mediated Th I immune response. However, these gene expression results should be interpreted with caution because they are based on a limited number of samples.
In order to confirm this hypothesis, we investigated whether the TNFRI.609(Gff) promoter polymorphism is involved in disrupting recognition of a potential binding site for a critical transcription factor that might influence TNFR I transcription level. Our predictive results using TOMTOM algorithm and TRANSFAC database suggest that the presence ofG allele at position -609 might disrupt the binding site to ICSBPIIRF-8 transcription factor. ICSBPIIRF-8 is a member of the IRF family oftranscription factors, which are important modulators of the IFNy signalling cascade and have been identified in association with the promoter region of numerous macrophage essential genes, such as IL12, IL1~, IL18, iNOS orISGI5 (37) . Further, several genes regulated by ICSBPIIRF-8 (e.g., MAP4K4, IL-17R, and SOCS7) are involved in different stages of the nuclear factor KB (NFKB) signalling pathway (37) . Therefore, we can postulate that ICSBPIIRF-8 transcription factor might also regulate the NFKB signaling pathway by its regulation ofthe TNFRI gene, the first gene in this signalling cascade. In support of this hypothesis, ICSBPIIRF-8 and TNFRI are known to be closely related genes, since ICSBPIIRF-8 has also been associated with an enhanced ubiquination of TNFR associated factor 6 (TRAF6), a protein that mediates signal transduction from members ofthe TNF receptor superfamily and activation ofAP-I and NFKB transcription factors (38) .
It has also been demonstrated that ICSBPIIRF-8 promotes the differentiation and activation of DCs and macrophage cells (39) and that TNFRI mRNA levels increase during this biological process (40) . Further, ICSBP/IRF-8 has been shown to have a critical role promoting essential genes in macrophages and to participate in the cell-mediated Thl immune response against pathogens (37, 39) . Thus, ICSBP/IRF-8 -1mice exhibit severe defects in both innate and adaptive immune response (37) . With this background, we hypothesized that the presence of TNFR 1.609(Gff) promoter polymorphisms can modify the binding affinity to ICSBP/IRF-8 and can therefore be used to predict susceptibility to infection and to facilitate the risk stratification of haematological patients.
In conclusion, the results of this study contribute to a better understanding of the complex association of TNFRI polymorphisms with IPA infection susceptibility. Our data suggest that susceptibility to IPA might be influenced by TNFRl. 609(Gff) polymorphism because the defective immune response to Aspergillus infections in haematological patients corresponds to an altered TNFRI function that disrupts protective, antifungal cell-mediated Th I responses. The biological relevance of the regulation ofmRNA TNFRI levels by TNFRI polymorphisms via ICSBP/IRF-8 transcription factor has yet to be defined. Nonetheless, TNFRI polymorphisms are associated with susceptibility to IPA, and a significantly lower level of TNFRI mRNA was observed in patients with a higher susceptibility to the infection. Therefore, TNFR I gene appears to be a candidate gene for orchestration of the cellmediated Th I response. However, these results need to be confirmed in a larger cohort ofhaematological patients, performing a functional analysis to establish the role of TNFRI. 609(Gff) polymorphism in mediating the binding of ICSBPIIRF-8 to the TNFR I promoter.
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